<DOC>
	<DOC>NCT00343915</DOC>
	<brief_summary>To evaluate the persistence of antibodies against hepatitis B at 30, 42, 54 and 66 months after the first dose of the hepatitis B primary vaccination course. Subjects were aged 11 to 15 years at the time of the primary vaccination course. At the time of enrollment in the present long-term follow-up study subjects were aged 13 to 18 years. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.</brief_summary>
	<brief_title>Immuno &amp; Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs</brief_title>
	<detailed_description>All subjects who participated in the primary study, in which they received either 2 or 3 doses of GSK Biologicals hepatitis B vaccine, and who consented to participate in the long-term follow-up at Month 42 were contacted by the investigators. No additional subjects will be recruited during this long-term follow-up study and no vaccine will be administered.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects have participated in primary study HBV280 Written informed consent will be obtained from each subject and/ or parent or guardian of the subject before the bloodsampling visit of each year</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Persistence</keyword>
	<keyword>Hepatitis B vaccine</keyword>
</DOC>